NQO1 Primary Antibody
|Aliases||DTD; QR1; DHQU; DIA4; NMOR1; NMORI|
|Formulation||Ascitic fluid containing 0.03% sodium azide. |
|Immunogen||Purified recombinant fragment of human NQO1 expressed in E. Coli. |
|Shipping Information||This product will ship in a box containing blue ice at a temperature of 4°C. Learn More|
|FCM (Flow Cytometry)||1/200 - 1/400|
|WB (Western Blot)||1/500 - 1/2000|
Contact us to order
Figure 1: Western blot analysis using NQO1 mAb against human NQO1 (AA: 134-274) recombinant protein. (Expected MW is 41.3 kDa)
Figure 2: Western blot analysis using NQO1 mouse mAb against A549 (1), Hela (2), MCF-7 (3) and HepG2 (4) cell lysate.
Figure 4: Flow cytometric analysis of HepG2 cells using NQO1 mouse mAb (green) and negative control (red).
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
This gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a cytoplasmic 2-electron reductase. This FAD-binding protein forms homodimers and reduces quinones to hydroquinones. This protein's enzymatic activity prevents the one electron reduction of quinones that results in the production of radical species. Mutations in this gene have been associated with tardive dyskinesia (TD), an increased risk of hematotoxicity after exposure to benzene, and susceptibility to various forms of cancer. Altered expression of this protein has been seen in many tumors and is also associated with Alzheimer's disease (AD). Alternate transcriptional splice variants, encoding different isoforms, have been characterized.
|References (references)||1. Mol Cancer Ther. 2009 Dec;8(12):3369-78. |
2. J Biol Chem. 2009 Nov 27;284(48):33233-41.